Drug Profile
IRX 2
Alternative Names: Citoplurikin; IRX-2Latest Information Update: 02 Jul 2023
Price :
$50
*
At a glance
- Originator IRX Therapeutics
- Developer City of Hope National Medical Center; Eterna Therapeutics; H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (USA); University of Southern California
- Class Antineoplastics; Cytokines
- Mechanism of Action Dendritic cell stimulants; Natural killer cell stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cervical intraepithelial neoplasia; Squamous cell cancer; Triple negative breast cancer; Vulvar intraepithelial neoplasia
- No development reported Liver cancer; Solid tumours
Most Recent Events
- 02 Jun 2023 Interim immunogenicity and adverse events data from the phase II NeoIRX trial in Triple-negative-breast cancer presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 02 Jun 2023 Brooklyn ImmunoTherapeutics terminates the phase-II NeoIRX trial in Triple-negative-breast cancer (Combination therapy, First-line therapy, Late-stage disease, Neoadjuvant therapy) in USA (SC) due to withdrawal of drug support for IRX-2 prior to June 2023 (NCT04373031)
- 17 Oct 2022 Brooklyn ImmunoTherapeutics is now called Eterna Therapeutics